Bellini_PDX1 | BRAF | Collecting duct (Bellini) | Baseline | CDDP + Gemcitabine + Bevacizumab | | BRAF:p.(Gly466Ala) | | Yes | Panel | Yes | No |
CB-01-002_PDX1 | KRAS | Lung | Baseline | Sotorasib | Cispltine-Pemetrexed-Pembrolizumab, Carboplatin-Pemetrexed-Pembrolizumab, Pembrolizumab | KRAS:p.(Gly12Cys) | | Yes | WES-RNAseq | Yes | Yes |
CB-01-003_PDX2 | KRAS | Lung | Progressive disease | Sotorasib | Carboplatin-Pemetrexed-Pembrolizumab, Carboplatin-Paclitaxel-Pembrolizumab | KRAS:p.(Gly12Cys) | | Yes | No | Yes | No |
CB-01-007_PDX1 | KRAS | Lung | Baseline | Sotorasib | Carboplatin-Pemetrexed-Pembrolizumab | KRAS:p.(Gly12Cys) | | Yes | No | Yes | No |
DSRCT-03_PDX1 | other | Prostate | | | | EWS::WT1 fusion | | No | No | Yes | No |
M2057_PDX1 | FGFR | Bladder | Progressive disease | Erdafitinib | MVAC | FGFR3:p.(Ser249Cys) | | Yes | WES-RNAseq | Yes | Yes |
M2267_PDX1 | other | NUT Midline | Progressive disease | BET inhibitor | | NUTM1 fusion | | Yes | No | Yes | No |
MR84_PDX1 | prostate | Prostate | Primary resistance | Enzalutamide | Docetaxel | TP53 deletion | NEPC | Yes | WES-RNAseq | Yes | Yes |
MR86_PDX1 | FGFR | Bladder | Progressive disease | Erdafitinib | Cisplatin | FGFR3:p.(Ser249Cys) | | Yes | WES-RNAseq | Yes | Yes |
MR86_PDX2 | FGFR | Bladder | Stable disease | Erdafitinib | Cisplatin | FGFR3:p.(Ser249Cys) | | Yes | WES-RNAseq | Yes | Yes |
MR10_PDX1 | other | Parotid gland | Progressive disease | NOTCH1 inhibitor | Pazopanib, 5-FU-Cisplatin | NOTCH1:p.(Ser2467*) | | Yes | WES-RNAseq | Yes | Yes |
MR1010_PDX1 | EGFR | Lung | Progressive disease | Osimertinib (first line) | | EGFR:p.(Leu858Arg) | | Yes | WES-RNAseq | Yes | No |
MR1016_PDX1 | HER2 | Lung | Baseline | Trastuzumab-deruxtecan | Carboplatin-Pemetrexed-Pembrolizumab | ERBB2:p.(Ala775_G776insTyrValMetAla) | | Yes | WES-RNAseq | Yes | No |
MR1025_PDX1 | DDR | Prostate | Progressive disease | Rucaparib | Enzalutamide, Docetaxel | BRCA2:p.(Cys2689fs*4) (germline), AR amplification | | Yes | No | Yes | No |
MR1029_PDX1 | KRAS | Lung | Baseline | Sotorasib | Pemetrexed-Platin-Pembrolizumab | KRAS:p.(Gly12Cys) | | Yes | WES-RNAseq | Yes | Yes |
MR1029_PDX2 | KRAS | Lung | On treatment | Sotorasib | Pemetrexed-Platin-Pembrolizumab | KRAS:p.(Gly12Cys) | | Yes | WES-RNAseq | Yes | No |
MR1029_PDX3 | KRAS | Lung | Progressive disease | Sotorasib | Pemetrexed-Platin-Pembrolizumab | KRAS:p.(Gly12Cys) | | Yes | WES-RNAseq | Yes | Yes |
MR103_PDX1 | FGFR | Bladder | Progressive disease | Erdafitinib | Carboplatin, Docetaxel | | | Yes | WES-RNAseq | Yes | Yes |
MR1030_PDX1 | Anaplastic thyroid | Thyroid | Progressive disease | CLEVER-1 inhibitor | Rx-carboplatin-Paclitaxel | TP53:p.(Arg280Thr) | | Yes | WES-RNAseq | Yes | No |
MR1031_PDX1 | KRAS | Lung | Progressive disease | Sotorasib | Cisplatin-Pemetrexed, Carboplatin-Paclitaxel-Pembrolizumab | KRAS:p.(Gly12Cys) | | Yes | No | Yes | Yes |
MR104_PDX1 | FGFR | Bladder | Progressive disease | Erdafitinib | Cisplatin, Carboplatin, Gemcitabine | FGFR3:p.(Ser249Cys) | | Yes | WES-RNAseq | Yes | No |
MR1055_PDX1 | NTRK | Lung | Baseline | Entrectinib | Carboplatin-Etoposide-Atezolizumab, Carboplatin-Paclitaxel-Bevacizumab | EML4::NTRK2 fusion, EGFR:p.(Leu858Arg) | | Yes | WES-RNAseq | Yes | No |
MR1108_PDX1 | BRAF | Thyroid | Baseline | Dabrafenib + Trametinib | | BRAF:p.(Val600Glu) | | Yes | WES-RNAseq | Yes | No |
MR1130_PDX1 | KRAS | Colon | Baseline (primary resistance) | JDQ443 + TNO155 | FOLFOX-bevacizumab, LV5FU2-bevacizumab, FOLFIRI-bevacizumab, LONSURF-bevacizumab | KRAS:p.(Gly12Cys) | | Yes | WES-RNAseq | Yes | No |
MR1148_PDX1 | FGFR | Cholangiocarcinoma | Baseline | | FOLFOX, FOLFIRI, Cisplatin-Gemcitabine | BICC1::FGFR2 fusion | | Yes | WES-RNAseq | Yes | No |
MR1154-R_PDX1 | FGFR | Pancreas | Progressive disease | | Futibatinib (TAS-120), FOLFOX, FOLFIRI ,Gemcitabine | FGFR2::CCSER2 fusion | | Yes | WES-RNAseq | Yes | No |
MR1156_PDX1 | EGFR | Lung | Progressive disease | Osimertinib | | EGFR:p.(Leu858Arg) | | Yes | WES-RNAseq | Yes | No |
MR1168_PDX1 | NTRK | Lung neuroendocrine | Progressive disease | Repotrectinib | Etoposide-Carboplatin-immunotherapie, Repotrectinib, Etoposide-Carboplatin-Larotrectinib | EML4::NTRK3 fusion | | Yes | WES-RNAseq | Yes | No |
MR1188_PDX1 | ALK | Lung | Progressive disease | Alectinib | | EML4::ALK fusion | | Yes | WES-RNAseq | Yes | No |
MR1197_PDX1 | DDR | Ovary | Progressive disease | Niraparib | Carboplatin-avastin | TP53:p.(Cys238Tyr), CDK12:p.(Leu636Phefs*4) | | Yes | WES-RNAseq | Yes | No |
MR122_PDX1 | DDR | Colon | Progressive disease | Ceralasertib + Carboplatin | FOLFOX, FOLFIRI | ATM:p.(Gln2811Ter) | | Yes | WES-RNAseq | Yes | Yes |
MR1220_PDX1 | EGFR | Lung | Progressive disease | Osimertinib | | EGFR:p.(Leu858Arg) | | Yes | WES-RNAseq | Yes | No |
MR123_PDX1 | prostate | Prostate | Primary resistance | Enzalutamide | Docetaxel, Abiraterone, Cabazitaxel | BRCA2 deletion | Luminal | Yes | WES-RNAseq | Yes | Yes |
MR1238_PDX1 | HER2 | Lung | Progressive disease | Trastuzumab-deruxtecan | RX-Durvalumab,Carboplatin-Paclitaxel-Pembrolizumab, Navelbin | ERBB2:p.(Ser310Phe), KRAS:p.(Gly12Asp) | | Yes | WES-RNAseq | Yes | No |
MR1247_PDX1 | KRAS | Pancreas | Baseline | screenfail MCLA-128 | FOLFIRINOX | KRAS:p.(Gly12Asp) | | Yes | WES-RNAseq | Yes | No |
MR1249_PDX1 | KRAS | Pancreas | Baseline | Trastuzumab-deruxtecan | FOLFIRINOX, Gemcitabine, FOLFOX, Paclitaxel | KRAS:p.(Gly12Asp) | | Yes | WES-RNAseq | Yes | No |
MR1253_PDX1 | EGFR | Lung | Baseline (sensitive) | ADC TROP2 | Osimertinib, Cisplatin + pemetrexed + pembrolizumab, Gemcitabine | EGFR deletion exon 19 | | Yes | WES | Yes | No |
MR1257_PDX1 | KRAS | Pancreas | Baseline | Gemcitabine + Paclitaxel | FOLFIRINOX | KRAS:p.(Gly12Asp) | | Yes | WES-RNAseq | Yes | No |
MR1259_PDX1 | KRAS | Pancreas | Baseline | screenfail MCLA-128 | FOLFIRINOX, Gemcitabine, Paclitaxel | KRAS:p.(Gly12Asp) | | Yes | WES-RNAseq | Yes | No |
MR1271_PDX1 | FGFR | Duodenum | Progressive disease | Futibatinib (TAS-120) | FOLFOX, FOLFIRI | FGFR2::NEK1 fusion | | Yes | WES-RNAseq | Yes | No |
MR1274_PDX1 | other | Pancreas | Baseline | | FOLFIRINOX, Gemcitabine-Paclitaxel | STAT3:p.(Asp661Val) | | Yes | WES-RNAseq | Yes | No |
MR1284_PDX1 | KRAS | Pancreas | Baseline | Brigatinib | Ceritinib | KRAS:p.(Gly12Asp) | | Yes | WES-RNAseq | Yes | No |
MR131_PDX1 | EGFR | Lung | Progressive disease | Osimertinib | Gefitinib, Rociletinb | EGFR:p.(Leu858Arg), EGFR p.(Thr790Met) | | Yes | WES-RNAseq | Yes | Yes |
MR135_PDX1 | ALK | Lung | Progressive disease | Lorlatinib | Crizotinib | EML4::ALK fusion | | Yes | WES-RNAseq | Yes | Yes |
MR135_PDX2 | ALK | Lung | Progressive disease | Lorlatinib | Crizotinib | EML4::ALK fusion | | Yes | WES-RNAseq | Yes | Yes |
MR14_PDX1 | other | Lung | Progressive disease | Everolimus | Pemetrexed-Cisplatin | MTOR:p.(Pro465Thr) | | Yes | No | Yes | No |
MR142_PDX1 | other | Adenoid cystic carcinoma | Progressive disease | NOTCH1 inhibitor | Cisplatin-Navelbin | NOTCH1:p.(Pro2465Argfs*11) | | Yes | WES-RNAseq | Yes | Yes |
MR144_PDX1 | ALK | Lung | Progressive disease | Brigatinib | Crizotinib, Ceritinib | EML4::ALK fusion | | Yes | WES-RNAseq | Yes | Yes |
MR15_PDX1 | FGFR | Bladder | Progressive disease | Erdafitinib | MVAC | FGFR3:p.(Ser249Cys) | | Yes | WES-RNAseq | Yes | Yes |
MR15_PDX2 | FGFR | Bladder | Stable disease | Erdafitinib | MVAC | FGFR3:p.(Ser249Cys) | | Yes | WES-RNAseq | Yes | Yes |
MR150_PDX1 | prostate | Prostate | Primary resistance | Abiraterone | Docetaxel, Cabazitaxel, Carboplatin | ATM:p.(Arg1466Pro) | Luminal | Yes | WES-RNAseq | Yes | Yes |
MR151_PDX1 | prostate | Prostate | Progressive disease | Enzalutamide | | CDK12:p.(Leu866Trp) | Mixed | Yes | WES-RNAseq | Yes | No |
MR156_PDX1 | EGFR | Lung | Progressive disease | Osimertinib | Erlotinib, Gefitinib, Cisplatin, Pemetrexed | EGFR deletion exon 19, EGFR:p.(Thr790Met) | | Yes | WES-RNAseq | Yes | Yes |
MR170_PDX1 | prostate | Prostate | Primary resistance | Abiraterone | Enzalutamide, Carboplatin | RB1 deletion | NEPC | Yes | WES-RNAseq | Yes | Yes |
MR174_PDX1 | FGFR | Cholangiocarcinoma | Progressive disease | Erdafitinib | Gemcitabine-Sunitinib-Everolimus-FOLFIRI | FGFR2:p.(Cys382Arg) | | Yes | WES-RNAseq | Yes | Yes |
MR178_PDX1 | prostate | Prostate | Progressive disease | Enzalutamide | | AR:p.(Leu702His), AR:p.(His790Arg), AR:p.(His875Tyr) | Luminal | Yes | WES-RNAseq | Yes | No |
MR182_PDX1 | prostate | Prostate | Baseline | Enzalutamide | | ATM:p.(Ile2998Argfs*9) (germline) | Luminal | Yes | WES-RNAseq | Yes | No |
MR182_PDX2 | prostate | Prostate | Progressive disease | Enzalutamide | | ATM:p.(Ile2998Argfs*9) (germline) | Mixed | Yes | WES-RNAseq | Yes | No |
MR191_PDX1 | prostate | Prostate | Primary resistance | Enzalutamide | Carboplatin | BRCA2:p.(Val2118_Glu2123delinsLeuThrGlnLysTrpLys), BRCA2:p.(Thr2125Asnfs*4) | NEPC | Yes | WES-RNAseq | Yes | Yes |
MR191_PDX2 | prostate | Prostate | Baseline | Enzalutamide | Docetaxel, Carboplatin | BRCA2:p.(Thr2125Asnfs*4) | NEPC | Yes | WES-RNAseq | Yes | Yes |
MR196_PDX1 | EGFR | Lung | Progressive disease | Erlotinib | | EGFR deletion exon 19, EGFR:p.(Thr790Met) | | Yes | WES-RNAseq | Yes | No |
MR202_PDX1 | EGFR | Lung | Progressive disease | Osimertinib | Carboplatin-paclitaxel-bevacizumab, Pemetrexed, Erlotinib | EGFR:p.(Leu858Arg), EGFR p.(Thr790Met) | | Yes | WES-RNAseq | Yes | No |
MR210_PDX1 | ALK | Lung | Progressive disease | Lorlatinib | Cisplatin, Crizotinib, Ceritinib | EML4::ALK fusion, ALK:p.(Cys1156Tyr) | | Yes | WES-RNAseq | Yes | Yes |
MR211_PDX1 | EGFR | Lung | Progressive disease | Erlotinib | Gefitinib | EGFR deletion exon 19, EGFR:p.(Thr790Met) | | Yes | WES-RNAseq | Yes | Yes |
MR221_PDX1 | EGFR | Lung | Progressive disease | Osimertinib | Gefitinib | EGFR deletion exon 19 | | Yes | WES-RNAseq | Yes | No |
MR228_PDX1 | EGFR | Lung | Progressive disease | Osimertinib | Gefitinib, Afatinib | EGFR deletion exon 19 | | Yes | WES-RNAseq | Yes | Yes |
MR240_PDX1 | EGFR | Lung | Progressive disease | Osimertinib | Erlotinib | EGFR deletion exon 19, EGFR:p.(Thr790Met) | | Yes | WES-RNAseq | Yes | Yes |
MR240_PDX2 | EGFR | Lung | Progressive disease | Brigatinib | Erlotinib, Osimertinib | EGFR deletion exon 19, EGFR:p.(Thr790Met) | | Yes | WES-RNAseq | Yes | No |
MR242_PDX1 | EGFR | Lung | Progressive disease | Osimertinib | Cisplatin, Gefitinib, Erlotinib, Carboplatin, Afatinib | EGFR deletion exon 19, EGFR:p.(Thr790Met) | | Yes | WES-RNAseq | Yes | Yes |
MR246_PDX1 | FGFR | Bladder | Progressive disease | Erdafitinib | Gemcitabine-Oxaliplatine, Carboplatin | FGFR3:p.(Ser249Cys) | | Yes | WES-RNAseq | Yes | No |
MR248_PDX1 | FGFR | Bladder | Progressive disease | Erdafitinib | Atezolizumab | FGFR3:p.(Tyr373Cys) | | Yes | WES | Yes | Yes |
MR260_PDX1 | EGFR | Lung | Progressive disease | Osimertinib | Afatinib, Gefitinib | EGFR deletion exon 19 | | Yes | WES-RNAseq | Yes | No |
MR283_PDX1 | prostate | Prostate | Progressive disease | Enzalutamide | Enzalutamide | AR amplification | Mixed | Yes | WES-RNAseq | Yes | No |
MR313_PDX1 | FGFR | Cholangiocarcinoma | Progressive disease | Pemigatinib | FOLFIRINOX, FOLFIRI | FGFR2::STRN4 | | Yes | WES-RNAseq | Yes | Yes |
MR320_PDX1 | BRAF | Lung | Progressive disease | Dabrafenib | Cisplatin-Vinorelbin | BRAF:p.(Val600Glu) | | Yes | WES-RNAseq | Yes | Yes |
MR322_PDX1 | EGFR | Lung | Progressive disease | Osimertinib | | EGFR deletion exon 19 | | Yes | WES-RNAseq | Yes | No |
MR332_PDX1 | FGFR | Cholangiocarcinoma | Progressive disease | Erdafitinib | Docetaxel, Carboplatin, FOLFIRI | FGFR2::BICC1 fusion | | Yes | WES-RNAseq | Yes | Yes |
MR341_PDX1 | KRAS | Lung | Baseline | Sotorasib | Cisplatin + navelbin, Nivolumab, Carboplatin-Pemetrexed-Bevacizumab, Paclitaxel-Bevacizumab | KRAS:p.(Gly12Cys) | | Yes | WES-RNAseq | Yes | Yes |
MR344_PDX1 | ALK | Lung | Progressive disease | Ceritinib | Crizotinib | EML4::ALK fusion | | Yes | WES-RNAseq | Yes | Yes |
MR347_PDX1 | ALK | Lung | Progressive disease | Ceritinib | Cisplatin-pemetrexed, Crizotinib | EML4::ALK fusion | | Yes | WES-RNAseq | Yes | Yes |
MR369_PDX1 | FGFR | Cholangiocarcinoma | Progressive disease | Pemigatinib | Gemcitabine-Oxaliplatine | FGFR2::INA fusion | | Yes | WES-RNAseq | Yes | Yes |
MR371_PDX2 | FGFR | Bladder | Progressive disease | Futibatinib (TAS-120) | Atezolizumab, Erdafitinib | FGFR3:p.(Tyr373Cys) | | Yes | WES-RNAseq | Yes | No |
MR387_PDX1 | EGFR | Lung | Progressive disease | Erlotinib | | EGFR deletion exon 19, EGFR:p.(Thr790Met) | | Yes | WES-RNAseq | Yes | Yes |
MR393_PDX1 | EGFR | Lung | Progressive disease | Osimertinib (first line) | | EGFR:p.(Leu858Arg) | | Yes | WES-RNAseq | Yes | Yes |
MR406_PDX1 | FGFR | Bladder | Progressive disease | Pemigatinib | carboplatin-Gemcitabine-Pembrolizumab | FGFR3:p.(Ser249Cys) | | Yes | WES-RNAseq | Yes | No |
MR41_PDX1 | prostate | Prostate | Baseline | Pre Abiraterone | | PTEN deletion | Luminal | Yes | WES-RNAseq | Yes | Yes |
MR411_PDX1 | FGFR | Bladder | Progressive disease | Pemigatinib | carboplatin-Gemcitabine-Pembrolizumab | FGFR3:p.(Tyr373Cys) | | Yes | WES-RNAseq | Yes | No |
MR415_PDX1 | BRAF | Appendix | Progressive disease | Vemurafenib | Cetuximab, FOLFOX, FOLFIRI, LV5FU2 | BRAF:p.(Val600Glu) | | Yes | WES-RNAseq | Yes | No |
MR41R_PDX1 | ALK | Unknown probably lung | | | | EML4::ALK, ALK:p.(Gly1202Arg), ALK:p.(Gly134Arg) | | No | WES-RNAseq | Yes | No |
MR432_PDX1 | other | DLBCL | Progressive disease | CMAK683X2101 EED inhibitor | CHOP, DHAP, GEMOX, ICE, Nivolumab, anti CD37, CC122, GA101, Tazemetostat, r-caelyx-endoxan-methotrexate, CMAK683X2101 (inhibiteur de EED) | TP53:p.(Arg175His) | | Yes | WES-RNAseq | Yes | No |
MR436_PDX1 | EGFR | Lung | Progressive disease | Erlotinib | | EGFR:p.(Leu858Arg) | | Yes | WES-RNAseq | Yes | No |
MR441_PDX1 | EGFR | Lung | Progressive disease | Osimertinib | Gefitinib | EGFR deletion exon 19, EGFR:p.(Thr790Met) | | Yes | WES-RNAseq | Yes | Yes |
MR445_PDX1 | EGFR | Lung | Progressive disease | Erlotinib | Carboplatin | EGFR deletion exon 19 | | Yes | WES-RNAseq | Yes | Yes |
MR448_PDX1 | ALK | Lung | Progressive disease | Lorlatinib | Crizotinib, Alectinib, Brigatinib | EML4::ALK fusion | | Yes | WES-RNAseq | Yes | Yes |
MR468_PDX1 | ALK | Lung | Progressive disease | Alectinib first line | Lorlatinib | EML4::ALK fusion | | Yes | WES-RNAseq | Yes | No |
MR478_PDX1 | EGFR | Lung | Progressive disease | Osimertinib (first line) | | EGFR deletion exon 19 | | Yes | WES-RNAseq | Yes | No |
MR480_PDX1 | ALK | Lung | Progressive disease | Lorlatinib | Crizotinib, Cisplatin | CD74::ROS1 fusion | | Yes | WES-RNAseq | Yes | No |
MR491_PDX1 | EGFR | Lung | Progressive disease | Osimertinib (first line) | | EGFR deletion exon 19 | | Yes | WES-RNAseq | Yes | No |
MR5_PDX1 | KRAS | Endometrial | Progressive disease | MEK inhibitor | Carboplatin, Paclitaxel | KRAS:p.(Gly12Asp) | | Yes | WES-RNAseq | Yes | Yes |
MR503_PDX1 | EGFR | Lung | Progressive disease | Osimertinib | Gefitinib | EGFR deletion exon 19 | | Yes | WES-RNAseq | Yes | No |
MR513_PDX1 | KRAS | Pancreas | Progressive disease | Sotorasib | FOLFIRINOX, FOLFIRI, Gemcitabine-Paclitaxel-FOLFOX | KRAS:p.(Gly12Cys), Deletion RB1 | | Yes | WES-RNAseq | Yes | No |
MR527_PDX1 | ALK | Lung | Progressive disease | Lorlatinib | Alectinib | EML4::ALK fusion | | Yes | WES-RNAseq | Yes | No |
MR556_PDX2 | EGFR | Lung | Progressive disease | Osimertinib | | EGFR:p.(Gly719Ala), EGFR:p.(Glu709Ala) (cis) | | Yes | WES-RNAseq | Yes | No |
MR563_PDX1 | BRAF | Thyroid | Progressive disease | Dabrafenib + Trametinib | | BRAF:p.(Val600Glu) | | Yes | WES-RNAseq | Yes | No |
MR57_PDX1 | ALK | Lung | Progressive disease | Lorlatinib | Crizotinib | EML4::ALK, ALK:p.(Cys1156Tyr) | | Yes | WES-RNAseq | Yes | Yes |
MR577_PDX1 | ALK | Lung | Progressive disease | Lorlatinib | | EML4::ALK fusion | | Yes | WES-RNAseq | Yes | No |
MR587_PDX1 | EGFR | Lung | Progressive disease | Osimertinib | Gefitinib, Cisplatin | EGFR deletion exon 19, EGFR:p.(Thr790Met) | | Yes | WES-RNAseq | Yes | Yes |
MR59_PDX1 | prostate | Prostate | Primary resistance | Enzalutamide | Docetaxel | Deletion RB1 | NEPC | Yes | WES-RNAseq | Yes | Yes |
MR590_PDX1 | EGFR | Lung | Progressive disease | Osimertinib | Gefitinib, Cisplatin | EGFR deletion exon 19, EGFR:p.(Thr790Met) | | Yes | WES-RNAseq | Yes | No |
MR600_PDX1 | ALK | Lung | Progressive disease | Alectinib | | EML4::ALK fusion | | Yes | WES-RNAseq | Yes | No |
MR600_PDX2 | ALK | Lung | Progressive disease | Alectinib | | EML4::ALK fusion | | Yes | WES-RNAseq | Yes | No |
MR602_PDX1 | FGFR | Cholangiocarcinoma | Progressive disease | Futibatinib (TAS-120) | FOLFOX, FOLFIRI, Gemcitabine-cipslatine, Docetaxel | FGFR2::MITF fusion | | Yes | WES-RNAseq | Yes | No |
MR619_PDX1 | ALK | Cholangiocarcinoma | Progressive disease | Alectinib | Gemcitabine-Cisplatin-Pembrolizumab, Nab-Paclitaxel-Gemcitabin | STRN::ALK fusion | | Yes | WES-RNAseq | Yes | Yes |
MR622_PDX1 | other | NUT Midline | Progressive disease | BET inhibitor | | BRD4::NUTM1 fusion | | Yes | WES-RNAseq | Yes | No |
MR646_PDX1 | FGFR | Cholangiocarcinoma | Progressive disease | Futibatinib (TAS-120) | Cisplatin-Gemcitabine,FOLFOX | FGFR2::TACC2 fusion | | Yes | WES-RNAseq | Yes | No |
MR696_PDX1 | DDR | Ovary | Progressive disease | Niraparib | Carboplatin-avastin | RAD51C:p.(Ile244fs*9), TP53:p.(Arg248Trp) | | Yes | No | Yes | No |
MR7_PDX1 | EGFR | Lung | Progressive disease | Osimertinib | Gefitinib, Erlotinib, Carboplatin, Cetuximab | EGFR:p.(Leu858Arg) | | Yes | WES-RNAseq | Yes | Yes |
MR701_PDX1 | FGFR | Cholangiocarcinoma | Baseline | Futibatinib (TAS-120) | FOLFOX, Gemcitabin-Cipslatin | FGFR2::ZMYM4 fusion | | Yes | WES-RNAseq | Yes | No |
MR719_PDX1 | FGFR | Cholangiocarcinoma | Baseline | Futibatinib (TAS-120) | FOLFOX, Cisplatin-Gemcitabin | FGFR2::SORBS2 fusion | | Yes | WES-RNAseq | Yes | No |
MR723_PDX1 | DDR | Gynecological | Progressive disease | Olaparib | Carboplatin-Paclitaxel, Carboplatin-Gemcitabine | BRCA2 (germline) | | Yes | No | Yes | No |
MR748_PDX1 | prostate | Prostate | Baseline | Enzalutamide | | NCOR2:p.(Gln667Alafs*37), PTEN deletion, TP53:p.(Ser149Profs*21) | | Yes | WES-RNAseq | Yes | No |
MR759_PDX1 | KRAS | Ovary | Progressive disease | Trametinib | Carboplatin-Docetaxel, Carboplatin-Doxorubicin-Bevacizumab, Carboplatin-Bevacuzimab+/-Atezolizumab, Doxorubicin | KRAS:p.(Gly12Asp) | | Yes | WES-RNAseq | Yes | No |
MR761_PDX1 | KRAS | Lung | Baseline | Sotorasib | Cisplatin-Pemetrexed-Pembrolizumab | KRAS:p.(Gly12Cys) | | Yes | WES-RNAseq | Yes | Yes |
MR77_PDX1 | prostate | Prostate | Primary resistance | Darolutamide | Docetaxel, Enzalutamide, Abiraterone | | Mixed | Yes | WES-RNAseq | Yes | Yes |
MR803_PDX1 | Anaplastic thyroid | Thyroid | Baseline (sensitive) | Dabrafenib + Trametinib | Rx + Cisplatin-Adriamycine | TP53:p.(Arg181His) | | Yes | WES-RNAseq | Yes | No |
MR820_PDX1 | EGFR | Lung | Baseline | Osimertinib | Gefitinib | EGFR deletion exon 19, EGFR:p.(Thr790Met) | | Yes | WES-RNAseq | Yes | No |
MR835_PDX1 | KRAS | Pancreas | Baseline (primary resistance) | IPH5201 +/- durvalumab +/- oleclumab | FOLFIRINOX, FOLFIRI, Eryaspase-gemcitabine-abraxane | KRAS:p.(Gly12Asp) | | Yes | WES-RNAseq | Yes | No |
MR835_PDX2 | KRAS | Pancreas | Baseline (primary resistance) | IPH5201 +/- Durvalumab +/- Oleclumab | FOLFIRINOX, FOLFIRI, Eryaspase-gemcitabine-abraxane | KRAS:p.(Gly12Asp) | | Yes | WES-RNAseq | Yes | No |
MR847_PDX1 | FGFR | Cholangiocarcinoma | Baseline | Pemigatinib | FOLFOX, Gemcitabine-Cisplatin | FGFR2::PHC1 fusion | | Yes | WES-RNAseq | Yes | No |
MR869_PDX1 | KRAS | Lung | Progressive disease | Sotorasib | Cisplatin-Pemetrexed-Pembrolizumab, Paclitaxel-Bevacizumab | KRAS:p.(Gly12Cys) | | Yes | WES-RNAseq | Yes | Yes |
MR87_PDX1 | BRAF | Collecting duct (Bellini) | Progressive disease | Trametinib | Cisplatin-Gemcitabine-Bevacizumab | BRAF:p.(Gly466Ala) | | Yes | WES-RNAseq | Yes | Yes |
MR87_PDX2 | BRAF | Collecting duct (Bellini) | Progressive disease | Trametinib | Cisplatin-Gemcitabine-Bevacizumab | BRAF amplification | | Yes | WES-RNAseq | Yes | No |
MR876_PDX1 | EGFR | Lung | Progressive disease | Osimertinib | | EGFR deletion exon 19 | | Yes | WES-RNAseq | Yes | No |
MR886_PDX1 | EGFR | Lung | Progressive disease | Osimertinib | Gefitinib | EGFR:p.(Leu858Arg) | | Yes | WES-RNAseq | Yes | No |
MR892_PDX1 | EGFR | Lung | Progressive disease | Osimertinib | Erlotinib | EGFR deletion exon 19 | | Yes | WES-RNAseq | Yes | No |
MR9_PDX1 | prostate | Prostate | Baseline | Enzalutamide | | BRCA2:p.(Glu49*) | Mixed | Yes | WES-RNAseq | Yes | Yes |
MR9_PDX2 | prostate | Prostate | Progressive disease | Atezolizumab | Enzalutamide | BRCA2:p.(Glu49*) | Mixed | Yes | WES-RNAseq | Yes | No |
MR9_PDX3 | prostate | Prostate | Progressive disease | Olaparib | Enzalutamide, Atezolizumab | BRCA2:p.(Glu49*) | NEPC | Yes | WES-RNAseq | Yes | No |
MR90_PDX1 | DDR | Endometrial | Stable disease | ATR inhibitor | Cisplatin, Paclitaxel, 5FU, Gemcitabine | ATM:p.(Ser2146Thr), ATRX:p.(Asp333Tyr) | | Yes | WES-RNAseq | Yes | Yes |
MR902_PDX1 | Anaplastic thyroid | Thyroid | Progressive disease | CLEVER-1 inhibitor | Cisplatin + Adriamycine + Rx | TP53:p.(Phe134fs*38) | | Yes | WES-RNAseq | Yes | No |
MR97_PDX1 | FGFR | Ovary | Progressive disease | Erdafitinib | Carboplatin, Pazopanib | FGFR2::FAM160B1 fusion | | Yes | WES-RNAseq | Yes | Yes |
MR97_PDX2 | FGFR | Ovary | Stable disease | Erdafitinib | Carboplatin, Pazopanib | FGFR2::FAM160B1 fusion | | Yes | WES-RNAseq | Yes | Yes |
RET-IGR-01_PDX1 | RET | Lung | Progressive disease | Selpercatinib | Pemetrexed-Carboplatin | KIF5B:RET fusion | | Yes | No | Yes | No |
ST-0293_PDX1 | KRAS | Colon | Progressive disease | | | KRAS:p.(Gly12Cys) | | No | No | Yes | No |
ST-0899_PDX1 | ALK | Lung | Progressive disease | Brigatinib | Alectinib | EML4::ALK fusion | | Yes | WES-RNAseq | Yes | No |
ST2099_PDX1 | KRAS | Pleural | Progressive disease | Sotorasib | Cisplatin-Navelbine, Carboplatin-Pemetrexed-Pembrolizumab | KRAS:p.(Gly12Cys) | | Yes | No | Yes | No |
ST-2405_PDX1 | FGFR | Cholangiocarcinoma | Progressive disease | | Gemcitabine-Cisplatin, FOLFOX | FGFR2:p.(Leu776fs*6) | | Yes | No | Yes | No |
ST-2543_PDX1 | FGFR | Cholangiocarcinoma | Progressive disease | | Gemcitabine-Cisplatin, FOLFOX | FGFR2::KIAA1217 fusion | | Yes | No | Yes | No |
ST2577_PDX1 | RET | Thyroid | Progressive disease | Selpercatinib | Iode 131, Lenvatanib | RET::NCOA4 fusion | | Yes | WES-RNAseq | Yes | No |
ST-2726_PDX2 | FGFR | Cholangiocarcinoma | Baseline | | Cisplatin-Gemcitabine, RLY-4008, FOLFOX, FOLFIRI, Paclitaxel | FGFR2::PLEKHA4 fusion | | Yes | No | Yes | No |
ST-3075_PDX1 | ROS1 | Lung | Progressive disease | | Letrozol, Exemestane, Anastrozole, Crizotinib | SDC4::ROS1 fusion | | Yes | No | Yes | No |
ST-3227_PDX1 | FGFR | Pancreas | Progressive disease | | FOLFIRINOX,FOLFIRI,LV5FU2,Carboplatin-gemcitabine | FGFR2::INA fusion | | Yes | No | Yes | No |
ST-3498_PDX1 | ALK | Lung | Progressive disease | Alectinib (primary resistance) | | EML4::ALK fusion | | Yes | WES-RNAseq | Yes | No |
ST3511_PDX1 | ROS1 | Lung | Baseline | | Cisplatin-Pemetrexed, Crizotinib, Lorlatinib, Carboplatin-Pemetrexed-Bevacizumab | CD74::ROS1 fusion | | Yes | WES-RNAseq | Yes | No |
ST3511_PDX2 | ROS1 | Lung | Progressive disease | | Cisplatin-Pemetrexed, Crizotinib, Lorlatinib, Carboplatin-Pemetrexed-Bevacizumab | CD74::ROS1 fusion | | Yes | No | Yes | No |
ST-3973_PDX2 | ALK | Lung | Progressive disease | Lorlatinib | Crizotinib | EML4::ALK fusion | | Yes | WES-RNAseq | Yes | No |
ST4029_PDX1 | Anaplastic thyroid | Thyroid | Baseline | Carboplatin + Paclitaxel | | ASXL1:p.(Gly643fs*15), TP53:p.(Glu286Lys) | | Yes | WES-RNAseq | Yes | No |
ST-4036_PDX1 | FGFR | Cholangiocarcinoma | Progressive disease | | Gemcitabine-Cisplatin, FOLFOX | FGFR2::WAC fusion | | Yes | No | Yes | No |
ST-4070_PDX1 | EGFR | Lung | Progressive disease | Osimertinib + Selpercatinib | | EGFR deletion exon 19 | | No | No | Yes | No |
ST-4085_PDX1 | EGFR | Lung | Progressive disease | Lazertinib - Amivantamab | Osimertinib | EGFR deletion exon 19 | | Yes | No | Yes | No |
ST-4193_PDX1 | FGFR | Cholangiocarcinoma | Progressive disease | | Gemcitabine-Oxaliplatin | FGFR2:p.(Cys382Arg) | | Yes | No | Yes | No |
ST-4352_PDX1 | EGFR | Lung | Progressive disease | Osimertinib | | EGFR deletion exon 19, KRAS:p.(Gly12Asp) | | Yes | No | Yes | No |
ST-4451_PDX1 | KRAS | Lung | Progressive disease | Sotorasib | Carboplatin-Paclitaxel-Pembrolizumab, Pembrolizumab | KRAS:p.(Gly12Cys) | | Yes | No | Yes | No |
ST-4764_PDX1 | KRAS | Lung | Baseline | | Carboplatin-pemetrexed-pembrolizumab, Carboplatin-pemetrexed, Docetaxel,Gemcitabine,Paclitaxel,SGNB6A-001 (intégrine 6) | KRAS:p.(Gly12Cys) | | Yes | No | Yes | No |
ST-4772_PDX1 | nectine-4 | Bladder | Baseline | | Avelumab, Carboplatin-Gemcitabine, Pembrolizumab | FGFR3:p.(Arg248Cys) | | Yes | No | Yes | No |
ST-5010_PDX1 | ALK | Lung | Baseline | | Cisplatin-Pemetrexed, Crizotinib, Lorlatinib, Carboplatin-pemetrexed-bevacizumab | EML4::ALK fusion | | Yes | No | Yes | No |
ST-5010_PDX2 | ALK | Lung | Progressive disease | | Cisplatin-Pemetrexed, Crizotinib, Lorlatinib, Carboplatin-pemetrexed-bevacizumab | EML4::ALK fusion | | Yes | No | Yes | No |
ST-5013_PDX1 | EGFR | Lung | Progressive disease | Osimertinib | | EGFR:p.(Leu858Arg) | | Yes | No | Yes | No |
ST-5016_PDX1 | KRAS | Lung | Baseline | Sotorasib | Cisplatin-vinorelbine-Rx, Durvalumab, Pembrolizumab | KRAS:p.(Gly12Cys) | | Yes | No | Yes | No |
ST-5242_PDX1 | FGFR | Bladder | Baseline | | MVAC, Pembrolizumab, Paclitaxel, Erdafitinib | FGFR3:p.(Tyr373Cys) | | Yes | No | Yes | No |
ST-5469_PDX1 | ALK | Lung | Baseline | | Alectinib,Lorlatinib, Cisplatin-Pemetrexed | EML4::ALK fusion | | Yes | No | Yes | No |
ST-5472_PDX1 | EGFR | Lung | Baseline | Osimertinib | Docetaxel | EGFR:p.(Leu858Arg) | | Yes | No | Yes | No |
ST-5526_PDX1 | nectine-4 | Bladder | Progressive disease | Enfortumab vedotin | Cisplatin-Gemcitabine, Carboplatin, Pembrolizumab | TP53, RB1 | | Yes | No | Yes | No |
ST-5923_PDX1 | EGFR | Lung | Progressive disease | Osimertinib | | EGFR deletion exon 19 | | Yes | No | Yes | No |
ST-5979_PDX1 | KRAS | Cholangiocarcinoma | Progressive disease | | Xeloda, Cisplatin-Durvalumab-Gemcitabine | KRAS:p.(Gly12Cys) | | Yes | No | Yes | No |
ST-6105_PDX1 | KRAS | Lung | Baseline | Sotorasib | Cisplatin-Pemetrexed-Pembrolizumab | KRAS:p.(Gly12Cys) | | Yes | No | Yes | No |
ST-6201_PDX1 | KRAS | Lung | Baseline | Sotorasib | Carboplatin-Pemetrexed-Pembrolizumab | KRAS:p.(Gly12Cys) | | Yes | No | Yes | No |
ST-6263_PDX1 | nectine-4 | Bladder | Baseline | | Cisplatin-Gemcitabine, Pembrolizumab | TP53, RB1, PTEN | | Yes | No | Yes | No |
ST-6372_PDX1 | KRAS | Lung | Baseline | Sotorasib | Carboplatin-Paclitaxel-Pembrolizumab | KRAS:p.(Gly12Cys) | | Yes | No | Yes | No |
ST-6566_PDX1 | EGFR | Lung | Progressive disease | Osimertinib | | EGFR | | No | No | Yes | No |
ST-6598_PDX1 | EGFR | Lung | Baseline | Osimertinib | | EGFR | | No | No | Yes | No |
ST-6714_PDX1 | KRAS | Lung | Baseline | Sotorasib | Cisplatin-vinorelbin, Cisplatin-Pemetrexed-Pembrolizumab, Dostarlimab-docetaxel, Docetaxel | KRAS:p.(Gly12Cys) | | Yes | No | Yes | No |
ST-7018_PDX1 | nectine-4 | Bladder | Baseline | | | | | No | No | Yes | No |